You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 16, 2025

List of Excipients in API DARIFENACIN HYDROBROMIDE


✉ Email this page to a colleague

« Back to Dashboard


Excipients in ANDA-approved (generic) drugs containing DARIFENACIN HYDROBROMIDE

Company Ingredient NDC Excipient
Par Pharmaceutical Inc darifenacin hydrobromide 10370-170 CALCIUM PHOSPHATE, DIBASIC, ANHYDROUS
Par Pharmaceutical Inc darifenacin hydrobromide 10370-170 D&C YELLOW NO. 10
Par Pharmaceutical Inc darifenacin hydrobromide 10370-170 FD&C YELLOW NO. 6
Par Pharmaceutical Inc darifenacin hydrobromide 10370-170 HYPROMELLOSE 2208
>Company >Ingredient >NDC >Excipient

Subscribe to access the full database, or Get Started Free

Detailed excipient profiles for DARIFENACIN HYDROBROMIDE

Excipient focus: ANHYDROUS DIBASIC CALCIUM PHOSPHATE

Excipient focus: CALCIUM PHOSPHATE, DIBASIC, ANHYDROUS

Excipient focus: D&C YELLOW NO. 10

Excipient focus: FD&C YELLOW NO. 6

Excipient focus: HYPROMELLOSE 2208

Excipient focus: HYPROMELLOSE 2910

Excipient focus: HYPROMELLOSES

Excipient focus: LACTOSE MONOHYDRATE

Excipient focus: MAGNESIUM STEARATE

Excipient focus: MALTODEXTRIN

Excipient focus: MEDIUM-CHAIN TRIGLYCERIDES

Excipient focus: POLYDEXTROSE

Excipient focus: POLYETHYLENE GLYCOL

Excipient focus: POLYETHYLENE GLYCOL 400

Excipient focus: POLYETHYLENE GLYCOL 4000

Excipient focus: POLYETHYLENE GLYCOL 8000

Excipient focus: POLYVINYL ALCOHOL

Excipient focus: TALC

Excipient focus: TITANIUM DIOXIDE

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

 
© Copyright 2002-2025 thinkBiotech LLC
ISSN: 2162-2639
Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2025 - 2026
 NCE-1 Patent Challenge Dates 2025 - 2026
Preferred Citation:

Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2025, www.DrugPatentWatch.com.
   See Primary Research Papers Citing DrugPatentWatch

Links